Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
$2.45
$2.45
$1.06
$2.70
$71.88M0.5179,750 shs64,728 shs
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$0.08
$0.49
$0.05
$23.40
$407K1.31.36 million shs23,154 shs
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$0.51
-1.9%
$0.50
$0.26
$1.14
$18.04M1.5831,517 shs7,595 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$2.84
+3.6%
$3.81
$2.60
$70.00
$15.65M0.11271,993 shs139,690 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
0.00%0.00%0.00%0.00%0.00%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
+3.90%+14.29%-81.47%-91.95%-99.34%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-5.50%+4.79%+15.04%+1.75%-44.88%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-0.72%-8.36%-4.20%-35.07%-91.70%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.38 of 5 stars
3.53.00.00.01.10.00.6
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
1.2514 of 5 stars
2.04.00.00.02.51.70.6
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
N/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
3.00
Buy$28.8835,548.15% Upside
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/A$3.80638.58% Upside
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
$21.92M3.28N/AN/A($0.56) per share-4.38
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
$320K1.27N/AN/A$1.74 per share0.05
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
$33.36M0.54N/AN/A$0.37 per share1.39
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.19M2.18N/AN/A($6.91) per share-0.41

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
-$5.96M-$0.27N/AN/AN/A-27.26%N/A-50.97%N/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
-$12.87M-$28.55N/AN/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
-$10.83M-$0.31N/AN/AN/A-32.47%-52.50%-17.66%5/20/2024 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-696.19%N/A-129.79%5/6/2024 (Confirmed)

Latest CASM, MOTS, TTOO, and SSKN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/A  
3/27/2024Q4 2023
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/A-$0.04-$0.04$0.03N/A$8.69 million
3/18/2024Q4 2023
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/A-$4.13-$4.13-$3.78N/A$0.06 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
N/AN/AN/AN/AN/A
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
N/AN/AN/AN/AN/A
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
N/A
2.33
2.04
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
0.46
1.76
1.69
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
1.19
1.28
1.06
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.45
0.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
27.61%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
20.06%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
32.43%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
37.60%
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
1.57%
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
40.43%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CAS Medical Systems, Inc. stock logo
CASM
CAS Medical Systems
7629.34 millionN/ANot Optionable
Motus GI Holdings, Inc. stock logo
MOTS
Motus GI
155.03 million4.95 millionNot Optionable
STRATA Skin Sciences, Inc. stock logo
SSKN
STRATA Skin Sciences
9935.06 million20.89 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
1135.51 million5.51 millionOptionable

CASM, MOTS, TTOO, and SSKN Headlines

SourceHeadline
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
globenewswire.com - April 24 at 9:00 AM
T2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head ContrastT2 Biosystems (NASDAQ:TTOO) versus Anika Therapeutics (NASDAQ:ANIK) Head to Head Contrast
americanbankingnews.com - April 22 at 1:26 AM
T2 Biosystems converts $15M loan to equity, aims for Nasdaq complianceT2 Biosystems converts $15M loan to equity, aims for Nasdaq compliance
investing.com - April 13 at 6:55 PM
T2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityT2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
finanznachrichten.de - April 12 at 9:52 AM
T2 Biosystems Shareholders Vote for CRG Debt Conversion into EquityT2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
globenewswire.com - April 11 at 4:05 PM
T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
finanznachrichten.de - March 28 at 11:09 AM
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
globenewswire.com - March 28 at 9:00 AM
T2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesT2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
finanznachrichten.de - March 20 at 4:39 PM
T2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick FactsT2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick Facts
markets.businessinsider.com - March 20 at 4:39 PM
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business UpdatesT2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
globenewswire.com - March 20 at 7:30 AM
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business UpdatesT2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
globenewswire.com - March 19 at 9:00 AM
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelT2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
globenewswire.com - March 18 at 9:00 AM
TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq ComplianceTTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance
investorplace.com - March 12 at 3:16 PM
T2 Biosystems Receives Extension From Nasdaq to Comply With Listing RequirementT2 Biosystems Receives Extension From Nasdaq to Comply With Listing Requirement
360dx.com - March 12 at 10:40 AM
T2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementT2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
finanznachrichten.de - March 12 at 10:40 AM
T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementT2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
globenewswire.com - March 12 at 9:00 AM
T2 Biosystems IncT2 Biosystems Inc
money.usnews.com - February 16 at 10:34 PM
T2 Biosystems (TTOO) share price stays stable post Q4 earningsT2 Biosystems (TTOO) share price stays stable post Q4 earnings
invezz.com - February 16 at 12:34 PM
T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call TranscriptT2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 16 at 12:34 PM
T2 Biosystems (TTOO) share price stays stable post Q4 earningsT2 Biosystems (TTOO) share price stays stable post Q4 earnings
invezz.com - February 16 at 11:09 AM
T2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaT2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
finanznachrichten.de - February 16 at 7:34 AM
Q4 2023 T2 Biosystems Inc Earnings CallQ4 2023 T2 Biosystems Inc Earnings Call
finance.yahoo.com - February 16 at 7:34 AM
T2 Biosystems Preliminary Q4 Revenues Down 69 PercentT2 Biosystems Preliminary Q4 Revenues Down 69 Percent
360dx.com - February 15 at 9:30 PM
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaT2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
finance.yahoo.com - February 15 at 4:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CAS Medical Systems logo

CAS Medical Systems

NASDAQ:CASM
CAS Medical Systems, Inc., a medical technology company, develops, manufactures, and markets non-invasive patient monitoring products worldwide. The company provides FORE-SIGHT tissue oximeter monitors, sensors, and accessories, as well as offers FORE-SIGHT ELITE monitors. Its FORE-SIGHT absolute tissue oximeter provides non-invasive and quantitative measurement of oxygenation for cerebral tissue during surgery or critical care situations. The company also offers repair services for parts. It markets products through its own sales force, distributors, and manufacturers' representatives, as well as through hospitals, surgery centers, and outpatient facilities. CAS Medical Systems, Inc. was founded in 1984 and is headquartered in Branford, Connecticut.
Motus GI logo

Motus GI

NASDAQ:MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.
STRATA Skin Sciences logo

STRATA Skin Sciences

NASDAQ:SSKN
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
T2 Biosystems logo

T2 Biosystems

NASDAQ:TTOO
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.